Investigation Report on China Follicle-Stimulating Hormone (FSH) Market, 2010-2019
Description
According to WHO’s evaluation, one in seven couples suffer from fertility which influences about 10%-15% of the world population. According to a survey, the number of patients with fertility accounts for 10% of married people, being double of 4.8% in 1984. The incidence of fertility in young people has increased and it is 15%-20% among women of childbearing age. For patients with hypothalamic-pituitary dysfunction including polycystic ovary syndrome, FSH can promote follicular development while in the case of blocked fallopian tube, unexplained fertility and fertility caused by male factor, FSH can do so in the assistive technology used to conceive the child.
FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSH?) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSH?) of Merck contributed USD 481 million with a market share of 37%. FSH develops fast after entering China, annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and CAGR during this period reaching 84.2%. Merck Serono (rhFSH?), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSH?) dominate the Chinese market, among which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.
As the number of patients suffering from infertility is huge in China, FSH has good market prospects.
Readers can get at least the following information from this report:
According to WHO’s evaluation, one in seven couples suffer from fertility which influences about 10%-15% of the world population. According to a survey, the number of patients with fertility accounts for 10% of married people, being double of 4.8% in 1984. The incidence of fertility in young people has increased and it is 15%-20% among women of childbearing age. For patients with hypothalamic-pituitary dysfunction including polycystic ovary syndrome, FSH can promote follicular development while in the case of blocked fallopian tube, unexplained fertility and fertility caused by male factor, FSH can do so in the assistive technology used to conceive the child.
FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSH?) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSH?) of Merck contributed USD 481 million with a market share of 37%. FSH develops fast after entering China, annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and CAGR during this period reaching 84.2%. Merck Serono (rhFSH?), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSH?) dominate the Chinese market, among which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.
As the number of patients suffering from infertility is huge in China, FSH has good market prospects.
Readers can get at least the following information from this report:
- market size of FSH in China
- competitive landscape of FSH in Chinese market
- price of FSH made by different enterprises in China
- market outlook of FSH in China
- manufacturers of endocrine regulator
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF FSH
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF FSH IN CHINA
2.1 Patent and Approval Status of FSH in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF FSH IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF FSH IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF FSH IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF FSH IN CHINESE HOSPITALS IN 2014
6.1 IBSA Institut Biochimique SA (SW) (Trade Name: Fostimon)
6.2 Livzon Pharmaceutical Group Co., Ltd (Trade Name: Hemei)
6.3 Merck Serono (Switzerland) (Trade Name: Gonal-f)
7 MAJOR MANUFACTURERS OF FSH IN CHINESE MARKET, 2010-2014
7.1 Livzon Pharmaceutical Group Co., Ltd
7.2 Merck Serono (Switzerland)
7.3 IBSA Institut Biochimique SA (Switzerland)
8 MARKET OUTLOOK OF FSH IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of FSH in China
Chart Sales Status of FSH in China, 2010-2014
Chart Sales Value of FSH in China, 2010-2014
Chart Sales Value of FSH in Some Regions in China, 2010-2014
Chart Sales Volume of FSH in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of FSH for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by Livzon in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by Merck Serono (Switzerland) in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of FSH for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of FSH Made by Livzon in China, 2010-2014
Chart Sales Volume and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
Chart Price of FSH Made by IBSA Institut Biochimique SA (SW) in Some Cities in China in 2014
Chart Price of FSH Made by Livzon Pharmaceutical Group Co., Ltd in Some Cities in China in 2014
Chart Price of FSH Made by Merck Serono (Switzerland) in Some Cities in China in 2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF FSH IN CHINA
2.1 Patent and Approval Status of FSH in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF FSH IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF FSH IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF FSH IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF FSH IN CHINESE HOSPITALS IN 2014
6.1 IBSA Institut Biochimique SA (SW) (Trade Name: Fostimon)
6.2 Livzon Pharmaceutical Group Co., Ltd (Trade Name: Hemei)
6.3 Merck Serono (Switzerland) (Trade Name: Gonal-f)
7 MAJOR MANUFACTURERS OF FSH IN CHINESE MARKET, 2010-2014
7.1 Livzon Pharmaceutical Group Co., Ltd
7.2 Merck Serono (Switzerland)
7.3 IBSA Institut Biochimique SA (Switzerland)
8 MARKET OUTLOOK OF FSH IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of FSH in China
Chart Sales Status of FSH in China, 2010-2014
Chart Sales Value of FSH in China, 2010-2014
Chart Sales Value of FSH in Some Regions in China, 2010-2014
Chart Sales Volume of FSH in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of FSH for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by Livzon in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
Chart Sales Value and Market Share of FSH Made by Merck Serono (Switzerland) in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of FSH for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of FSH Made by Livzon in China, 2010-2014
Chart Sales Volume and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
Chart Price of FSH Made by IBSA Institut Biochimique SA (SW) in Some Cities in China in 2014
Chart Price of FSH Made by Livzon Pharmaceutical Group Co., Ltd in Some Cities in China in 2014
Chart Price of FSH Made by Merck Serono (Switzerland) in Some Cities in China in 2014
